ZAI LAB LIMITED Net Income (Loss) Available to Common Stockholders, Diluted
ZAI LAB LIMITED (ZLAB) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$175.54 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-02-26
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2023-12-31 was -$95.43M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$69.15M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$120.89M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2023-03-31 was -$49.14M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for fiscal 2025 was -$175.54M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for fiscal 2024 was -$257.10M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for fiscal 2023 was -$334.62M.
- ZAI LAB LIMITED net income (loss) available to common stockholders, diluted for fiscal 2022 was -$443.29M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$175.54M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | -$257.10M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | -$95.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$164.58M derived: sum of 2 quarters · filed 2026-02-26 | -$285.48M derived: sum of 3 quarters · filed 2026-02-26 | -$334.62M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$69.15M 10-Q · filed 2023-11-07 | -$190.05M derived: sum of 2 quarters · filed 2023-11-07 | -$239.19M 10-Q · filed 2023-11-07 | -$300.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$120.89M 10-Q · filed 2023-08-07 | -$170.04M 10-Q · filed 2023-08-07 | -$231.81M derived: sum of 3 quarters · filed 2025-02-27 | -$393.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$49.14M 10-Q · filed 2023-05-09 | -$110.91M derived: sum of 2 quarters · filed 2025-02-27 | -$272.10M derived: sum of 3 quarters · filed 2025-02-27 | -$410.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$61.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$222.96M derived: sum of 2 quarters · filed 2025-02-27 | -$360.89M derived: sum of 3 quarters · filed 2025-02-27 | -$443.29M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$161.19M 10-Q · filed 2023-11-07 | -$299.12M derived: sum of 2 quarters · filed 2023-11-07 | -$381.52M 10-Q · filed 2023-11-07 | -$593.34M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$137.93M 10-Q · filed 2023-08-07 | -$220.33M 10-Q · filed 2023-08-07 | -$432.15M derived: sum of 3 quarters · filed 2024-02-27 | -$528.56M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$82.39M 10-Q · filed 2023-05-09 | -$294.22M derived: sum of 2 quarters · filed 2024-02-27 | -$390.63M derived: sum of 3 quarters · filed 2024-02-27 | -$553.96M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$211.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$308.24M derived: sum of 2 quarters · filed 2024-02-27 | -$471.56M derived: sum of 3 quarters · filed 2024-02-27 | -$704.47M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$96.41M 10-Q · filed 2022-11-09 | -$259.74M derived: sum of 2 quarters · filed 2022-11-09 | -$492.65M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$163.32M 10-Q · filed 2022-08-09 | -$396.23M 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | -$268.90M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |